Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.

about

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

P2860

Q54977541-765949B2-40CA-48A7-91FF-A0FF4F981A4D

P2860

Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q48022028

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Cost-effectiveness of osimerti ...... 0M non-small cell lung cancer.

@en

Cost-effectiveness of osimerti ...... 0M non-small cell lung cancer.

@nl

type

Item

label

Cost-effectiveness of osimerti ...... 0M non-small cell lung cancer.

@en

Cost-effectiveness of osimerti ...... 0M non-small cell lung cancer.

@nl

prefLabel

Cost-effectiveness of osimerti ...... 0M non-small cell lung cancer.

@en

Cost-effectiveness of osimerti ...... 0M non-small cell lung cancer.

@nl

P1476

Cost-effectiveness of osimerti ...... 90M non-small cell lung cancer

@en

P2093

Carolyn Bodnar

http://www.w3.org/2001/XMLSchema#string

Evelina Bertranou

http://www.w3.org/2001/XMLSchema#string

Matthew Dyer

http://www.w3.org/2001/XMLSchema#string

Samuel Large

http://www.w3.org/2001/XMLSchema#string

Viktor Dansk

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.

Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Health state utilities for non small cell lung cancer.

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

P304

113-121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13696998.2017.1377718

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alastair Peter Greystoke

P577

2017-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28880737

http://www.w3.org/2001/XMLSchema#string

Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.

about

P2860

P2860

Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698